Venus is the second planet from the Sun in our solar system.
金星是我们太阳系中距离太阳第二近的行星。
Named after the Roman goddess of love and beauty,
Venus is often referred to as the Morning Star or the Evening Star.
金星以罗马爱与美之神的名字命名，常被称为晨星或暮星。
Venus has a thick, toxic atmosphere primarily composed of carbon dioxide with clouds of sulfuric acid.
金星拥有一层主要由二氧化碳构成的浓厚有毒大气层，云层中含有硫酸。
Due to its dense atmosphere,
Venus experiences a greenhouse effect, resulting in a surface temperature hot enough to melt lead.
由于其浓厚的大气层，金星产生了强烈的温室效应，地表温度高到足以熔化铅。
Venus rotates very slowly, taking 243 Earth days to complete one rotation, making its day longer than its year (225 Earth days).
金星自转非常缓慢，完成一次自转需要243个地球日，这使得它的昼长超过了它的年（225个地球日）。
The planet
Venus does not have any moons.
金星没有卫星。
The Soviet Union's Venera missions were the first to successfully land on
Venus and transmit data back to Earth in the 1970s and 1980s.
苏联的金星号任务在1970年代和1980年代首次成功登陆金星，并将数据传回地球。
Venus has a similar size and mass to Earth, leading some to consider it as a "sister" planet.
金星的大小和质量与地球相似，因此有人将其视为“姐妹”行星。
The topography of
Venus features vast plains and numerous mountains, including the highest mountain on any planet in our solar system, Maxwell Montes.
金星的地貌包括广阔的平原和众多山脉，其中马克斯韦尔山脉是太阳系中最高的山。
Future exploration of
Venus aims to unravel the mysteries of its past, such as whether it once had oceans and a more temperate climate.
对金星的未来探索旨在揭示其过去的谜团，比如它是否曾经拥有海洋和更温和的气候。
Chinese heart disease treatment company Venus Medtech has acquired the Israeli company Cardiovalve for $300 million, both companies said in a joint statement on Wednesday.
两家公司周三在一份联合声明中表示，中国心脏病治疗公司Venus Medtech以3亿美元收购了以色列公司Cardiovalve。
Founded in 2009 and headquartered in China's eastern city of Hangzhou, Venus Medtech is a leader in transcatheter heart valvular therapies in China.
Venus Medtech成立于2009年，总部位于中国东部城市杭州，是中国经导管心脏瓣膜治疗的领导者。
The acquisition is intended to expand Venus Medtech's product layout of valve replacement and accelerate its innovation and internationalization, the statement said.
声明称，此次收购旨在扩大Venus Medtech的瓣膜置换产品布局，加速其创新和国际化。
"The acquisition of Cardiovalve will further consolidate our leading position in the field of structural heart disease in China and globally", said Eric Zi, chief executive officer of Venus Medtech.
Venus Medtech首席执行官Eric Zi表示：“收购Cardiovalve将进一步巩固我们在中国和全球结构性心脏病领域的领先地位。”。
"Cooperation with Venus Medtech will accelerate our development in the global market, especially the Chinese market, and achieve more breakthrough innovations", said Amir Gross, chief executive officer of Cardiovalve.
Cardiovalve首席执行官Amir Gross表示：“与Venus Medtech的合作将加速我们在全球市场，特别是中国市场的发展，并实现更多突破性创新。”。
DCP recently announced that it has reached a definitive agreement with Venus Medtech for an equity investment.
Venus Medtech is dedicated to providing cardiovascular products for structural heart disease and its first generation of trans-catheter aortic valve replacement or TAVR product, Venus A, was the first such product in the country approved by the China Food and Drug Administration in April 2017.
The investment will facilitate Venus Medtech's development of its sales network to establish the leading position in China's TAVR market, Wayne Wang, managing director of DCP, said.
Moreover, DCP is delighted to have the opportunity to invest in Venus Medtech given the company's outstanding management team, strong technological capabilities and deep industry knowledge," Liu said.
As the first company that has been granted approval by the CFDA for a TAVR product, Venus Medtech has a critical first-mover advantage in China that has proven to be extremely durable in other markets.